With a revenue increase of 12.45% in the second quarter 2026, year on year to cumulative value of $12,587 million, Vertex Pharmaceuticals Inc's revenue per employee grew on a trailing twelve months basis to $ 31,079,506. The productivity of Vertex Pharmaceuticals Inc's employees was 0.0%, above the company average. Within the Healthcare sector Vertex Pharmaceuticals Inc achieved the highest revenue per employee. While Vertex Pharmaceuticals Inc's total ranking has deteriorated compared to the previous quarter from 14 to 28. Vertex Pharmaceuticals Inc has 405 employees.
Vertex Pharmaceuticals Secures FDA Approval for JOURNAVX, Marks New Revenue Milestone Vertex Pharmaceuticals Incorporated has announced a significant breakthrough in pain management with the FDA s approval of JOURNAVX (suzetrigine), a first-in-class oral, non-opioid treatment for adults experiencing moderate-to-severe acute pain. This innovative medication acts as a highly selective NaV1.8 pain signal inhibitor, addressing a critical need for effective pain relief without the risk of addiction commonly associated with traditional opioid therapies. The FDA s approval signals a pivotal moment not only for Vertex but also for the broader pharmaceutical landscape, as JOURNAVX offers a non-addictive alternative for patients suffering from various forms of acute pain. The medication is now indicated for use across diverse pain conditions, reinforcing Vertex’s commitment to developing novel therapeutic options in the healthcare sector.In parallel with this notable regulatory achievement, Vertex Pharmaceuticals has reported a promising financial performance. The company’s revenue per employee has risen to $1,967,741 on a trailing twelve-month basis, representing an 11.61% increase in revenue for the third quarter of 2024, year-on-year, and bringing the cumulative revenue to an impressive $10,626 million. This achievement marks a new company high, underscoring Vertex s robust growth trajectory amidst evolving market conditions.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
